Risk factors for ductal, lobular, and mixed ductal-lobular breast cancer in a screening population

Cancer Epidemiology Biomarkers and Prevention

Volumn 19, Issue 6, 2010, Pages 1643-1654

  Phipps, Amanda I ^a,b   Li, Christopher I ^a,b   Kerlikowske, Karla ^d   Barlow, William E ^a,b,c   Buist, Diana S M ^b,c  

^a Fred Hutchinson Cancer Research Center   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

^c GROUP HEALTH RESEARCH INSTITUTE   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ANAMNESIS; ARTICLE; BREAST CANCER; CANCER CLASSIFICATION; CANCER RISK; CANCER SCREENING; CONTROLLED STUDY; ECHOMAMMOGRAPHY; FEMALE; HISTOPATHOLOGY; HORMONAL THERAPY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; CARCINOMA, LOBULAR; COHORT ANALYSIS; MIDDLE AGED; PATHOLOGY; RISK FACTOR; UNITED STATES; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; CARCINOMA, LOBULAR; COHORT STUDIES; FEMALE; HUMANS; MIDDLE AGED; RISK FACTORS; UNITED STATES;

EID: 77953302054     PISSN: 10559965     EISSN: None     Source Type: Journal    
DOI: 10.1158/1055-9965.EPI-10-0188     Document Type: Article

References (47)

1. Davis RP, Nora PF, Kooy RG, Hines JR. Experience with lobular carcinoma of the breast. Emphasis on recent aspects of management. Arch Surg 1979;114:485-8.
2. Loo LW, Grove DI, Williams EM, et al. Array comparative genomic hybridization analysis of genomic alterations in breast cancer subtypes. Cancer Res 2004;64:8541-9.
3. Gunther K, Merkelbach-Bruse S, Amo-Takyi BK, Handt S, Schroder W, Tietze L. Differences in genetic alterations between primary lobular and ductal breast cancers detected by comparative genomic hybridization. J Pathol 2001;193:40-7.
4. Nishizaki T, Chew K, Chu L, et al. Genetic alterations in lobular breast cancer by comparative genomic hybridization. Int J Cancer 1997;74:513-7.
5. Acs G, Lawton TJ, Rebbeck TR, LiVolsi VA, Zhang PJ. Differential expression of E-cadherin in lobular and ductal neoplasms of the breast and its biologic and diagnostic implications. Am J Clin Pathol 2001;115:85-98. (Pubitemid 33695094)
6. Li CI, Uribe DJ, Daling JR. Clinical characteristics of different histologic types of breast cancer. Br J Cancer 2005;93:1046-52.
7. Coradini D, Pellizzaro C, Veneroni S, Ventura L, Daidone MG. Infiltrating ductal and lobular breast carcinomas are characterised by different interrelationships among markers related to angiogenesis and hormone dependence. Br J Cancer 2002;87:1105-11.
8. Aldaz CM, Chen T, Sahin A, Cunningham J, Bondy M. Comparative allelotype of in situ and invasive human breast cancer: high frequency of microsatellite instability in lobular breast carcinomas. Cancer Res 1995;55:3976-81.
9. Wohlfahrt J, Mouridsen H, Andersen PK, Melbye M. Reproductive risk factors for breast cancer by receptor status, histology, laterality and location. Int J Cancer 1999;81:49-55. (Pubitemid 29124196)
10. Li CI, Malone KE, Porter PL, et al. Relationship between long durations and different regimens of hormone therapy and risk of breast cancer. JAMA 2003;289:3254-63.
11. Li CI, Malone KE, Porter PL, Weiss NS, Tang MT, Daling JR. Reproductive and anthropometric factors in relation to the risk of lobular and ductal breast carcinoma among women 65-79 years of age. Int J Cancer 2003;107:647-51.
12. Ursin G, Bernstein L, Lord SJ, et al. Reproductive factors and subtypes of breast cancer defined by hormone receptor and histology. Br J Cancer 2005;93:364-71.
13. Garcia-Closas M, Brinton LA, Lissowska J, et al. Established breast cancer risk factors by clinically important tumour characteristics. Br J Cancer 2006;95:123-9.
14. Li CI, Daling JR, Malone KE, et al. Relationship between established breast cancer risk factors and risk of seven different histologic types of invasive breast cancer. Cancer Epidemiol Biomarkers Prev 2006;15:946-54.
15. Rosenberg LU, Magnusson C, Lindstrom E, Wedren S, Hall P, Dickman PW. Menopausal hormone therapy and other breast cancer risk factors in relation to the risk of different histological subtypes of breast cancer: a case-control study. Breast Cancer Res 2006;8:R11.
16. Beaber EF, Holt VL, Malone KE, Porter PL, Daling JR, Li CI. Reproductive factors, age at maximum height, and risk of three histologic types of breast cancer. Cancer Epidemiol Biomarkers Prev 2008;17:3427-34.
17. Brinton LA, Richesson D, Leitzmann MF, et al. Menopausal hormone therapy and breast cancer risk in the NIH-AARP Diet and Health study cohort. Cancer Epidemiol Biomarkers Prev 2008;17:3150-60.
18. Couto E, Banks E, Reeves G, Pirie K, Beral V. Family history and breast cancer tumour characteristics in screened women. Int J Cancer 2008;123:2950-4.
19. Calle EE, Feigelson HS, Hildebrand JS, Teras LR, Thun MJ, Rodriguez C. Postmenopausal hormone use and breast cancer associations by hormone regimen and histologic subtype. Cancer 2009;115:936-45.
20. Reeves GK, Pirie K, Green J, Bull D, Beral V. Reproductive factors and specific histological types of breast cancer: prospective study and meta-analysis. Br J Cancer 2009;100:538-44.
21. Slanger TE, Chang-Claude JC, Obi N, et al. Menopausal homone therapy and risk of clinical breast cancer subtypes. Cancer Epidemiol Biomarkers Prev 2009;18:1188-96.
22. Reeves GK, Beral V, Green J, Gathani T, Bull D. Hormonal therapy for menopause and breast-cancer risk by histological type: a cohort study and meta-analysis. Lancet Oncol 2006;7:910-8.
23. Li CI, Littman AJ, White E. Relationship between age maximum height is attained, age at menarche, and age at first full-term birth and breast cancer risk. Cancer Epidemiol Biomarkers Prev 2007;16:2144-9.
24. Levi F, Te VC, Randimbison L, La Vecchia C. Increase in lobular breast cancer incidence in Switzerland. Int J Cancer 2003;107:164-5, author reply 166.
25. Verkooijen HM, Fioretta G, Vlastos G, et al. Important increase of invasive lobular breast cancer incidence in Geneva, Switzerland. Int J Cancer 2003;104:778-81.
26. Ballard-Barbash R, Taplin SH, Yankaskas BC, et al. Breast Cancer Surveillance Consortium: a national mammography screening and outcomes database. AJR Am J Roentgenol 1997;169:1001-8.
27. http://breastscreening.cancer.gov/data/elements.html.
28. http://breastscreening.cancer.gov/data/bcsc-data-definitions.pdf.
29. Kalbfleisch JD, Prentice RL. The Statistical Analysis of Failure Time Data. 2nd ed. New York (NY): John Wiley & Sons, Inc.; 2002.
30. Morimoto LM, White E, Chen Z, et al. Obesity, body size, and risk of postmenopausal breast cancer: the Women's Health Initiative (United States). Cancer Causes Control 2002;13:741-51.
31. Lahmann PH, Hoffmann K, Allen N, et al. Body size and breast cancer risk: findings from the European Prospective Investigation into Cancer And Nutrition (EPIC). Int J Cancer 2004;111:762-71.
32. Li CI, Malone KE, Daling JR. Interactions between body mass index and hormone therapy and postmenopausal breast cancer risk (United States). Cancer Causes Control 2006;17:695-703. (Pubitemid 43668328)
33. Kerlikowske K, Miglioretti DL, Ballard-Barbash R, et al. Prognostic characteristics of breast cancer among postmenopausal hormone users in a screened population. J Clin Oncol 2003;21:4314-21.
34. American College of Radiology. American College of Radiology Breast Imaging Reporting and Data System (BI-RADS). Reston (VA): American College of Radiology; 2003.
35. Tice JA, Cummings SR, Smith-Bindman R, Ichikawa L, Barlow WE, Kerlikowske K. Using clinical factors and mammographic breast density to estimate breast cancer risk: development and validation of a new predictive model. Ann Intern Med 2008;148:337-47.
36. Raghunathan TE, Lepkowski JM, Van Hoewyk J, Solenberger P. A multivariate technique for multiply imputing missing values using a sequence of regression models. Surv Methodol 2001;27:85-95.
37. Li CI, Weiss NS, Stanford JL, Daling JR. Hormone replacement therapy in relation to risk of lobular and ductal breast carcinoma in middle-aged women. Cancer 2000;88:2570-7.
38. Chen CL, Weiss NS, Newcomb P, Barlow W, White E. Hormone replacement therapy in relation to breast cancer. JAMA 2002;287:734-41.
39. Daling JR, Malone KE, Doody DR, et al. Relation of regimens of combined hormone replacement therapy to lobular, ductal, and other histologic types of breast carcinoma. Cancer 2002;95:2455-64.
40. Rossouw JE, Anderson GL, Prentice RL, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. JAMA 2002;288:321-33.
41. Anderson GL, Limacher M, Assaf AR, et al. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial. JAMA 2004;291:1701-12.
42. Kerlikowske K, Miglioretti DL. Effects of estrogen-only treatment in postmenopausal women. JAMA 2004;292:684-5, author reply 685-6.
43. Azzopardi GJ. Problems in Breast Pathology. pp. 240-257Philadelphia: WB Saunders; 1979.
44. International Classification of Diseases for Oncology. 2nd ed. Geneva: WHO; 1990.
45. Ghosh K, Brandt KR, Sellers TA, et al. Association of mammographic density with the pathology of subsequent breast cancer among postmenopausal women. Cancer Epidemiol Biomarkers Prev 2008;17:872-9.
46. McTiernan A, Martin CF, Peck JD, et al. Estrogen-plus-progestin use and mammographic density in postmenopausal women: Women's Health Initiative randomized trial. J Natl Cancer Inst 2005;97:1366-76.
47. Greendale GA, Reboussin BA, Slone S, Wasilauskas C, Pike MC, Ursin G. Postmenopausal hormone therapy and change in mammographic density. J Natl Cancer Inst 2003;95:30-7.